Cancer patients with neutropenic septic shock: etiology and antimicrobial resistance
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Among patients with febrile neutropenia that developed after chemotherapy, high-risk patients, such as those having clinical instability or Multinational Association of Supportive Care in Cancer score of < 21, require hospitalization for intravenous empiric antibiotic therapy. Monotherapy with an anti-pseudomonal ß-lactam agent is recommended. Although many studies reported the microbial etiology of infections and resistant patterns of febrile neutropenia, the patients were not well characterized as having neutropenic septic shock. Therefore, this study aimed to determine the microbial spectrum of infections and resistance patterns of their isolates in patients with chemotherapy-induced neutropenic septic shock. Methods: Data of adult patients diagnosed with neutropenic septic shock in the emergency department between June 2012 and December 2016 were extracted from a prospectively compiled septic shock registry at a single academic medical center. Thereafter, microbiological studies and antimicrobial susceptibility tests were conducted. Results: In total, 109 bacteria were found in patients with neutropenic septic shock. Gram-negative bacteria were the predominant causative organisms (84, 77.1%). Moreover, 33 microorganisms (30.3%) were multidrug-resistant (MDR) bacteria with extended-spectrum β-lactamase-producing Escherichia coli (17, 50%) being the commonest. The most commonly affected sites in patients with MDR bacterial infections were the gastrointestinal tract (45%) and unknown (43.5%). Approximately 48.5% of MDR bacteria were resistant to cefepime but not to piperacillin- tazobactam or carbapenem. Conclusions: MDR bacteria were prevalent in patients with chemotherapy-induced neutropenic septic shock. Therefore, piperacillin-tazobactam or carbapenem may be considered as empiric antibiotics if MDR bacteria are suspected to be causative agents.
Abstract
Background/Aims: Among patients with febrile neutropenia that developed after chemotherapy, high-risk patients, such as those having clinical instability or Multinational Association of Supportive Care in Cancer score of < 21, require hospitalization for intravenous empiric antibiotic therapy. Monotherapy with an anti-pseudomonal ß-lactam agent is recommended. Although many studies reported the microbial etiology of infections and resistant patterns of febrile neutropenia, the patients were not well characterized as having neutropenic septic shock. Therefore, this study aimed to determine the microbial spectrum of infections and resistance patterns of their isolates in patients with chemotherapy-induced neutropenic septic shock. Methods: Data of adult patients diagnosed with neutropenic septic shock in the emergency department between June 2012 and December 2016 were extracted from a prospectively compiled septic shock registry at a single academic medical center. Thereafter, microbiological studies and antimicrobial susceptibility tests were conducted. Results: In total, 109 bacteria were found in patients with neutropenic septic shock. Gram-negative bacteria were the predominant causative organisms (84, 77.1%). Moreover, 33 microorganisms (30.3%) were multidrug-resistant (MDR) bacteria with extended-spectrum β-lactamase-producing Escherichia coli (17, 50%) being the commonest. The most commonly affected sites in patients with MDR bacterial infections were the gastrointestinal tract (45%) and unknown (43.5%). Approximately 48.5% of MDR bacteria were resistant to cefepime but not to piperacillin- tazobactam or carbapenem. Conclusions: MDR bacteria were prevalent in patients with chemotherapy-induced neutropenic septic shock. Therefore, piperacillin-tazobactam or carbapenem may be considered as empiric antibiotics if MDR bacteria are suspected to be causative agents.
참고문헌 (22)
- Penack O, "Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO)", Ann Hematol, 93, pp.1083~1095 (2014)
- Barie PS, "Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection", Surg Infect (Larchmt), 6, pp.41~54 (2005)
- Freifeld AG, "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the Infectious Diseases Society of America", Clin Infect Dis, 52, pp.427~431 (2011)
- 이동건, "Evidence-Based Guidelines for Empirical Therapy of Neutropenic Fever in Korea", The Korean Journal of Internal Medicine, 26(2), pp.220~252 (2011), 대한내과학회
- Trecarichi EM, "Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey", Clin Microbiol Infect, 21, pp.337~343 (2015)
- Montassier E, "Recent changes in bacteremia in patients with cancer : a systematic review of epidemiology and antibiotic resistance", Eur J Clin Microbiol Infect Dis, 32, pp.841~850 (2013)
- Wang L, "Prevalence of resistant gram-negative bacilli in bloodstream infection in febrile neutropenia patients undergoing hematopoietic stem cell transplantation: a single center retrospective cohort study", Medicine (Baltimore), 94, pp.e1931~ (2015)
- Bone RC, "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP", SCCM Consensus Conference Committee. American College of Chest Physicians, Chest, pp.1992, 101[DOI]
- Levy MM, "2001 SCCM", ESICM, ATS, pp.SIS international sepsis definitions conference, Intensive Care Med[DOI]
- Singer M, "The third international consensus definitions for sepsis and septic shock(Sepsis-3)", JAMA, 315, pp.801~810 (2016)
- Kruse JM, "Neutropenic sepsis in the ICU : outcome predictors in a two-phase model and microbiology findings", Crit Care Res Pract, 2016, pp.8137850~ (2016)
- Dellinger RP, "Surviving sepsis campaign : international guidelines for management of severe sepsis and septic shock : 2012", Crit Care Med, 41, pp.580~637 (2013)
- Magiorakos AP, "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria : an international expert proposal for interim standard definitions for acquired resistance", Clin Microbiol Infect, 18, pp.268~281 (2012)
- Zanetti G, "Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients : a multicenter, evaluator-blind, prospective, randomized study", Antimicrob Agents Chemother, 47, pp.3442~3447 (2003)
- Goethaert K, "Highdose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients", Clin Microbiol Infect, 12, pp.56~62 (2006)
- Seo YB, "Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli", BMC Infect Dis, 17, pp.404~ (2017)
- Lee NY, "Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae : MIC matters", Clin Infect Dis, 56, pp.488~495 (2013)
- Kim SH, "Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever : factors associated with extended-spectrum β-lactamase production and its impact on outcome", Ann Hematol, 92, pp.533~541 (2013)
- Chong CY, "Infections in acute lymphoblastic leukaemia", Ann Acad Med Singapore, 27, pp.491~495 (1998)
- Evans SE, "Pneumonia in the neutropenic cancer patient", Curr Opin Pulm Med, 21, pp.260~271 (2015)
- Moet GJ, "Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe:report from the SENTRY Antimicrobial Surveillance Program (1998-2004)", Diagn Microbiol Infect Dis, 57, pp.7~13 (2007)
- Sunder S, "Life-threatening Escherichia coli cellulitis in patients with haematological malignancies", J Med Microbiol, 61(Pt 9), pp.1324~1327 (2012)